Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that suppressing allopregnanolone production in late gestation fetal sheep altered CNS activity and behavioral responses to transient asphyxia, effects mitigated by an analog co-infusion.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

In this study, a high prevalence of anabolic-androgenic steroid use was observed among bodybuilding athletes in Sergipe, Brazil, regardless of their socioeconomic backgrounds, highlighting the need for increased awareness about the associated health risks.

This study found that a microneedle patch using manganese thiophosphite showed greater hair regrowth potential compared to minoxidil, even with less frequent application, for treating androgenetic alopecia.

In this study, treatment with DHEA induced mild to moderate hyperplasia of sebaceous glands in ovariectomized rats, which was prevented by the antiandrogen Flutamide but not by the antiestrogen EM-800.

In a cell-free test setting, this study found that a novel saw palmetto extract effectively inhibited the 5α-reductase type II enzyme, showing promising bioactivity comparable to finasteride for promoting prostate health.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This article reviews the development of selective androgen receptor modulators and myostatin inhibitors as performance-enhancing drugs, highlighting ongoing challenges in achieving truly tissue-selective anabolic agents and reporting no new experimental findings.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

This article discusses laboratory and physical markers that may help detect androgenic anabolic steroid abuse in athletes and reports no new primary research results.

This study found that androgens increase Odc1 expression in skeletal muscle myoblasts, promoting proliferation and delaying differentiation.

This study found that delmadinone acetate and finasteride caused a reversible suppression of prostate gland activity in male dogs, with delmadinone acetate also temporarily altering epididymal sperm maturation.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

This study found that in sleep-deprived rats, increased 5α-reductase expression and activity in the prefrontal cortex contributed to psychosis- and mania-like symptoms, which finasteride ameliorated in a dose-dependent manner.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This study found no elevation of serum DHEA-S levels in men with androgenetic alopecia and observed no correlation between DHEA-S levels and the clinical stage of the condition.

This study found that finasteride administered for 28 days had no significant effect on adrenal steroidogenesis in healthy men, aside from inhibiting androstenedione metabolism.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This study found that incorporating steroid hormones into DPPC liposomes altered their physicochemical properties, including size, zeta potential, and phase transition temperatures.

This study developed a new measurement procedure using isotope dilution-liquid chromatography-tandem mass spectrometry for accurate quantification of DHEAS in human serum or plasma, demonstrating high selectivity, sensitivity, and low measurement uncertainty, making it suitable for routine standardization and clinical evaluation.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

In this study, nine male cases of androgenetic alopecia showed marked improvement after receiving systemic dexpanthenol treatment.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This study found that pregnane derivatives with higher lipophilicity, like compound 9d, had stronger androgen receptor binding and greater antiandrogenic effects in rats, correlating relative binding affinity with log P values.